Quotation mark

I’ve been

CLL progression-free
and treatment-free

since my 70th birthday.

That was almost 2 years ago.

VENCLEXTA + GAZYVA® (obinutuzumab)
is designed to be completed in 12 months
CHEMO-FREE

In a clinical trial with a 28-month median follow-up, 13% of patients on VENCLEXTA + GAZYVA had disease progression or died vs 37% of patients on chemoimmunotherapy. More than half were progression-free and treatment-free 5 years after completing chronic lymphocytic leukemia treatment.

Individual results may vary.

Actor portrayal.

REAL PATIENT STORIES

Hear a VENCLEXTA patient’s thoughts on the benefits of having time off CLL treatment.

Sign up for more info on VENCLEXTA,
including tools and resources to help you
make an informed treatment decision.

Have questions about your treatment with VENCLEXTA?

Call our nurse* support line for VENCLEXTA.

You can speak with our Registered Nurses* about your treatment with VENCLEXTA—at no cost to you.

Call our nurse support line:
Monday–Friday, 7am–7pm CST

Call our nurse support line:

Monday-Friday, 7am–7pm CST

*The nurses from the nurse support line are provided by AbbVie and do not work under the direction of a healthcare professional (HCP) or give medical advice. They are trained to direct patients to their HCP for treatment-related advice, including further referrals.